Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

• Published in: Annals of oncology Vol. 31; no. 3; pp. 334 - 351
• Main Authors: Chen, L.-T., Martinelli, E., Cheng, A.-L., Pentheroudakis, G., Qin, S., Bhattacharyya, G.S., Ikeda, M., Lim, H.-Y., Ho, G.F., Choo, S.P., Ren, Z., Malhotra, H., Ueno, M., Ryoo, B.-Y., Kiang, T.C., Tai, D., Vogel, A., Cervantes, A., Lu, S.-N., Yen, C.-J., Huang, Y.-H., Chen, S.-C., Hsu, C., Shen, Y.-C., Tabernero, J., Yen, Y., Hsu, C.-H., Yoshino, T., Douillard, J.-Y.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2020
• Subjects: Asia; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - therapy; China; consensus; ESMO guidelines; HCC; hepatocellular carcinoma; Humans; India; Japan; Liver Neoplasms - diagnosis; Liver Neoplasms - therapy; Malaysia; Medical Oncology; Pan-Asian; Republic of Korea; Taiwan; Asia; China; Japan; Taiwan; Malaysia; Republic of Korea; India; consensus; HCC; Pan-Asian; ESMO guidelines; hepatocellular carcinoma
• ISSN: 0923-7534; 1569-8041; 1569-8041
• DOI: 10.1016/j.annonc.2019.12.001

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treatment of HCC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with intermediate and advanced/relapsed HCC representing the oncology societies of Taiwan (TOS), China (CSCO), India (ISMPO) Japan (JSMO), Korea (KSMO), Malaysia (MOS) and Singapore (SSO). The voting was based on scientific evidence, and was independent of the current treatment practices, the drug availability and reimbursement situations in the individual participating Asian countries.